Journal Title：Journal Of Inflammation-london

Journal of Inflammation welcomes research submissions on all aspects of inflammation.

The five classical symptoms of inflammation, namely redness (rubor), swelling (tumour), heat (calor), pain (dolor) and loss of function (functio laesa), are only part of the story. The term inflammation is taken to include the full range of underlying cellular and molecular mechanisms involved, not only in the production of the inflammatory responses but, more importantly in clinical terms, in the healing process as well. Thus the journal covers molecular, cellular, animal and clinical studies, and related aspects of pharmacology, such as anti-inflammatory drug development, trials and therapeutic developments. It also considers publication of negative findings.

Journal of Inflammation aims to become the leading online journal on inflammation and, as online journals replace printed ones over the next decade, the main open access inflammation journal. Open access guarantees a larger audience, and thus impact, than any restricted access equivalent, and increasingly so, as the escalating costs of printed journals puts them outside University budgets. The unrestricted access to research findings in inflammation aids in promoting dynamic and productive dialogue between industrial and academic members of the inflammation research community, which plays such an important part in the development of future generations of anti-inflammatory therapies.

《炎癥雜志》歡迎有關(guān)炎癥各個方面的研究投稿。

炎癥的五種典型癥狀，即發(fā)紅 (rubor)、腫脹 (tumour)、發(fā)熱 (calor)、疼痛 (dolor) 和功能喪失 (functio laesa)，只是炎癥的一部分。炎癥一詞涵蓋了所涉及的所有潛在細胞和分子機制，不僅涉及炎癥反應(yīng)的產(chǎn)生，更重要的是，從臨床角度來看，也涉及愈合過程。因此，該雜志涵蓋了分子、細胞、動物和臨床研究，以及藥理學的相關(guān)方面，例如抗炎藥物開發(fā)、試驗和治療發(fā)展。它還考慮發(fā)表負面發(fā)現(xiàn)。

《炎癥雜志》旨在成為領(lǐng)先的炎癥在線雜志，并且隨著在線雜志在未來十年取代印刷雜志，成為主要的開放獲取炎癥雜志。與任何限制性訪問相比，開放獲取可以保證更大的受眾，從而產(chǎn)生更大的影響，而且隨著印刷期刊成本的不斷上升超出大學預算，開放獲取的影響力也越來越大。不受限制地獲取炎癥研究成果有助于促進炎癥研究界的工業(yè)和學術(shù)成員之間進行動態(tài)和富有成效的對話，這對未來幾代抗炎療法的發(fā)展起著重要作用。

Journal Of Inflammation-london創(chuàng)刊于2004年，由BioMed Central出版商出版，收稿方向涵蓋IMMUNOLOGY全領(lǐng)域，此刊是中等級別的SCI期刊，所以過審相對來講不是特別難，但是該刊專業(yè)認可度不錯，仍然是一本值得選擇的SCI期刊 。平均審稿速度 12周，或約稿 ，影響因子指數(shù)4.4，該期刊近期沒有被列入國際期刊預警名單，廣大學者值得一試。